Canada - English - Health Canada

angita pharma inc. - rosuvastatin (rosuvastatin calcium) - tablet - 40mg - rosuvastatin (rosuvastatin calcium) 40mg - hmg-coa reductase inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 20 mg - rosuvastatin calcium tablets are indicated as an adjunct to diet to: ●       reduce ldl-c, total-c, non-hdl-c and apo-b in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., ldl apheresis). pediatric use information for patients ages 8 to less than 10 years is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavaila

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 5 mg - rosuvastatin calcium tablets are indicated as an adjunct to diet to: pediatric use information for patients ages 8 to less than 10 years is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin calcium tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin calcium tabl

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 5mg - rosuvastatin (rosuvastatin calcium) 5mg

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 10mg - rosuvastatin (rosuvastatin calcium) 10mg

Canada - English - Health Canada

nora pharma inc - rosuvastatin (rosuvastatin calcium) - tablet - 20mg - rosuvastatin (rosuvastatin calcium) 20mg